Sex-Dimorphic Hormonal Signaling in Sarcopenia (Apelin–Insulin–Oxytocin)
Current understanding
Narrative review evidence [expert-opinion] proposes that skeletal muscle aging follows partially non-overlapping hormonal trajectories in men and women, with apelin (myokine/adipokine), insulin (anabolic/nutrient-sensing), and oxytocin (regenerative signaling) each showing sex-dimorphic declines and downstream effects on satellite-cell function, protein balance, and neuromuscular junction integrity. The synthesis is [mechanism-plausible] at the level of individual hormone–muscle axes but has no primary comparative human trial data yet; the clinical pitch of sex-stratified sarcopenia therapy currently outruns interventional evidence.
Evidence log
- 2026-04-13 — The metabolic-inflammatory axis in aging: A multi-organ framework anchored in Sarcopenia - A review.: cross-connection with sarcopenia-glam-metabolic-inflammatory-axis: GLAM framework anchors multi-organ metabolic-inflammatory aging on sarcopenia; the sex-dimorphic apelin/insulin/oxytocin page adds hormonal patterning of that same muscle-anchored axis. (novelty: 3)
- 2026-06-26 — Hormonal dimorphism in sarcopenia disease.: cross-connection with menopause-estrogen-decline: Menopausal sex-steroid loss is proposed as an entry point into the female-specific apelin/insulin/oxytocin sarcopenia trajectory, linking the primary-driver framing to a concrete muscle-aging mechanism. (novelty: 3)